Printer Friendly

Transcept resubmits NDA for Intermezzo.

M2 PHARMA-September 29, 2011-Transcept resubmits NDA for Intermezzo(C)2011 M2 COMMUNICATIONS

29 September 2011 - US Transcept Pharmaceuticals Inc (NASDAQ:TSPT) said on Tuesday it had resubmitted to the US Food and Drug Administration (FDA) the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual tablet).

The company is developing Intermezzo as a prescription sleep aid for use as needed when a middle of the night awakening is followed by difficulty returning to sleep.

The resubmission follows a meeting between Transcept and the agency on 14 September 2011 to discuss issues raised by the FDA in the July 2011 Complete Response letter.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 29, 2011
Previous Article:Onyx seeks FDA nod for carfilzomib in multiple myeloma.
Next Article:US Medical Protective to take over Princeton Insurance.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters